Navigation Links
ThermoGenesis Corp. and TotipotentSC Receive Approval for Phase Ib Clinical Trial of Res-Q™ 60 BMC for Treatment of Critical Limb Ischemia

RANCHO CORDOVA, Calif., Jan. 26, 2011 /PRNewswire/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products and services that process and store adult stem cells, and TotipotentSC, a U.S. company with a large India presence in medical devices, cellular therapy and clinical research management, announced today they have received approval from Fortis Escorts' (New Delhi) Independent Ethics Committee to proceed with a Phase Ib clinical trial in patients suffering from Non-Reconstructable Critical Limb Ischemia (CLI) utilizing ThermoGenesis' Res-Q™ 60 BMC system.

CLI, an advanced stage of peripheral artery disease, is characterized by peripheral arterial obstruction resulting in a severe reduction in blood flow to the extremities (hands, feet and legs).  This chronic vascular disorder presents symptoms progressing from mild discomfort to severe rest pain, skin ulcers and major tissue death.  CLI may result in limb amputation if not properly treated.  CLI afflicts millions of patients globally, and has a significant impact in the Indian population.  As such, CLI is a heavy burden on the Indian healthcare system with an estimated 20 million patients suffering from various stages of the disease.

The objectives of the trial are to assess safety and efficacy of stem cells derived from autologous concentrated bone marrow prepared using the Res-Q system.  Specific primary endpoints include safety of the cell processing and delivery plus limb salvage rates in 15 patients suffering from the most advanced stage of peripheral artery disease.  Each enrolled patient will have been determined medically unsuitable for further traditional modalities of treatment.  

The Res-Q system is CE-Marked for Europe and is an exempt Class I device in the U.S. as a laboratory single use sterile (disposable) bone marrow concentration device.  

"We are pleased to manage this clinical trial in collaboration with ThermoGenesis.  The trial will be conducted at the prestigious Escorts Heart Institute in New Delhi, which is part of the Fortis Healthcare network where TotipotentSC has a long term exclusive partnership for advancing the clinical adoption of adult cellular therapies," said Ken Harris, Chairman and CEO of MK Alliance, Inc. the parent company of TotipotentSC.

"We are looking forward to the initiation of enrollment in this clinical evaluation and are pleased to be collaborating with TotipotentSC as it shepherds the process in-country.  The early experience with the Res-Q in orthopedic procedures has been positive and we believe it will prove to be a valuable tool in treating CLI patients.  In addition, these types of clinical programs are an integral element of our strategy to increase awareness of and appreciation for the effectiveness of the device," said J. Melville Engle, Chairman and Chief Executive Officer of ThermoGenesis.

About TotipotentSCTotipotentSC, headquartered in Los Angeles and New Delhi, is a subsidiary of MK Alliance, Inc., a privately held company focused on the clinical scale up, manufacturing, and testing of cellular therapy devices.  MK Alliance, Inc. also holds a majority ownership in TotipotentRX Corporation, which focuses on the scale-up, manufacturing and delivery of adult cellular therapies, having world class GMP facilities in Gurgaon, India.

About ThermoGenesis Corp.ThermoGenesis Corp. ( is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products.  These include:

  • The BioArchive® System, an automated cryogenic device, used by cord blood stem cell banks in more than 30 countries for cryopreserving and archiving cord blood stem cell units for transplant.
  • AXP® AutoXpress™ Platform (AXP), a proprietary family of automated devices that includes the AXP and the MXP™ MarrowXpress™ and companion sterile blood processing disposables for harvesting stem cells in closed systems.  The AXP device is used for the processing of cord blood.  The MXP is used for the preparation of cell concentrates, including stem cells, from bone marrow aspirates in the laboratory setting.
  • The Res-Q™ 60 BMC (Res-Q), a point-of-care system designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates.
  • The CryoSeal® FS System, an automated device and companion sterile blood processing disposable, used to prepare fibrin sealants from plasma in about an hour.  The CryoSeal FS System is approved in the U.S. for liver resection surgeries.  The CryoSeal FS System has received the CE-Mark which allows sales of the product throughout the European community.

  • This press release contains forward-looking statements.  These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements.  Several factors including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2011, and introduction of competitive products and other factors beyond our control could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2011.  A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.ThermoGenesis Corp.Web site: http://www.thermogenesis.comContact: Investor Relations+1-916-858-5107,

    SOURCE ThermoGenesis Corp.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. ThermoGenesis Corp. Files Shelf Registration Statement on Form S-3
    2. ThermoGenesis Signs Major Bone Marrow Product Distribution Agreement in China
    3. ThermoGenesis Reports 35 Percent Increase in First Quarter 2011 Revenues, Adds Strategic Advisor and Inks China Distribution Deal With Nanshan Memorial Medical Institute
    4. ThermoGenesis Corp. to Announce First Quarter Fiscal 2011 Results on November 4, 2010
    5. ThermoGenesis Announces Platelet Rich Plasma (PRP) Res-Q Cardiovascular Licensing Agreement
    6. ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000
    7. ThermoGenesis Regains Compliance With NASDAQ Listing Rules
    8. ThermoGenesis Announces Reverse Stock Split Effective on NASDAQ Capital Market August 27, 2010
    9. ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program
    10. ThermoGenesis Names Jorge Artiles Vice President, Chief Quality and Regulatory Affairs Officer
    11. ThermoGenesis Announces National Institute of Health Grant
    Post Your Comments:
    (Date:10/12/2015)...  In a Sutter Institute of Medical Research study ... and Psychiatry, the blood product intravenous immunoglobulin, or IVIG, ... in patients in the early, pre-dementia phase of Alzheimer,s ... IVIG, extracted from the plasma of more than 1,000 ... protein found in patients with Alzheimer,s disease. Sutter Institute ...
    (Date:10/12/2015)... 2015 Leadership of the National Association of Vision ... Aspasia Shappet , CEO of MESVision resumed her role ... Board at its annual strategic planning meeting in ... of the organization from May 2013 to May of this ... as a result of the increased demands of his recent ...
    (Date:10/12/2015)... 12, 2015  CME Group,s Center for Innovation ... of Theranos, is the 11 th recipient of the ... revolutionary blood diagnostics company, Theranos , to change health ... a new era of preventive care. CME Group will present ... Conference in Naples, Florida , on ...
    Breaking Medicine Technology:
    (Date:10/13/2015)... ... ... In an age where the cost of energy is rising, Susquehanna ... in 2009. The Williamsport Regional Medical Center (WRMC) campus has grown 50 percent since ... , According to Facilities Management Administrative Director Dieter Reichmann, this is the result ...
    (Date:10/13/2015)... ... October 13, 2015 , ... NavaFit Inc. today announced the ... others to train with, participate in local fitness & sporting events, and stay ... , “As high medical costs drive us to get more serious about fitness and ...
    (Date:10/13/2015)... ... October 13, 2015 , ... Altec Products, Inc., ... Sponsorship of Synergy 2015. The annual WennSoft KEY2ACT user conference will take place ... will unite customers, partners, WennSoft team members and sponsors to facilitate the sharing ...
    (Date:10/13/2015)... ... October 13, 2015 , ... Georgia Partnership for TeleHealth ... throughout Georgia, along with affiliate organizations, Alabama Partnership for Telehalth (ATP) and Florida ... for Fall 2015. , Each of the three conferences share this year’s ...
    (Date:10/13/2015)... ... October 13, 2015 , ... Local Gold’s Gym franchise owner, Bryce Berry, ... August 26. Berry, who owns and operates Gold's Gym Cheyenne in Cheyenne, ... Gyms in the United States. A brand leader in global fitness, Gold’s Gyms are ...
    Breaking Medicine News(10 mins):